User Safety

Baytril offers a high degree of safety to the user and a high safety margin in cases of accidental misuse.

Product safety studies in several species of laboratory animals were performed according to internationally accepted guidelines.

A subcutaneous dose of 500 mg Enrofloxacin (= 5 ml Baytril® Max)/kg bw was tolerated by rats without mortality and without systemic signs. Similarly, acute dermal doses of 4000 mg Baytril® Max (= 400 mg Enrofloxacin)/kg bw caused no such effects in the rat.

Baytril® Max showed no skin sensitisation potential in a study with guinea pigs. Additionally, an acute skin irritation test in rabbits revealed no product-related lesions or any systemic intolerance reactions.

An acute eye irritation study was performed by instillation of Baytril® Max or Baytril® 10% injectable solution into the conjunctival sac of rabbits. Cornea, iris and conjunctivae were not affected and again there were no signs of systemic intolerance.

Ocular testing of Enrofloxacin conducted with New Zealand white rabbits demonstrated that the active ingredient may elicit ocular irritation, which was reversible within seven days.

Care should therefore be taken to prevent accidental ocular exposure when using Baytril. If such exposure does occur, the eyes should be flushed with copious amounts of water.